New Hermia release

Stockholm, Sweden – July 3, 2025 – Hermes Medical Solutions (HMS), a global leader in molecular imaging and dosimetry software, announces the latest CE-marked release* of its flagship platform, Hermia, featuring new capabilities designed to elevate precision, standardization, and efficiency in nuclear medicine.

A major highlight of this release is the integration of the Centiloid scale, a standardized method for quantifying amyloid PET imaging results. The Centiloid scale offers clinicians a consistent 0–100 range to interpret amyloid plaque burden, anchored by young healthy controls (Centiloid value = 0) and typical Alzheimer’s disease patients (Centiloid value = 100) [1].

“We are excited to introduce the Centiloid scale into our offering, anchoring Hermes Medical Solutions at the forefront of brain imaging,” said Tom Francke, CEO.

With this update, clinicians can now:

• Interpret amyloid PET results across different tracers and protocols using a unified standard.
• Enhance patient selection and treatment monitoring through improved comparability of quantitative imaging.
• Optimize FDG brain scan analysis with on-the-fly normalization method changes, supported by side-by-side 3D visualizations of deviation images. 
• Simultaneously display regions of both hyper- and hypometabolism in FDG brain scans for richer diagnostic context.
• Analyze novel 3D digital SPECT/CT images with extended visualization and comparison capabilities.

In addition, Hermia now supports loading CT-based anatomical regions for organ dosimetry. Users can seamlessly integrate external segmentation software with automatic region delineation and alignment, significantly streamlining the dosimetry workflow.

The release also brings enhanced manual motion correction tools for planar dynamic images, particularly benefiting renogram acquisitions where patient motion can impact image quality.

This latest version of Hermia continues HMS’s commitment to supporting clinicians with powerful, vendor-neutral tools for accurate diagnostics and efficient workflows—regardless of scanner type or radiopharmaceutical used.

Reference

[1] Klunk WE, et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11(1):1–15.e1–4. doi:10.1016/j.jalz.2014.07.003

*May be subject to regulatory clearance in your market. Not for sale in the USA.

About Hermes Medical Solutions

Since its establishment in 1976, in Stockholm, Sweden, Hermes Medical Solutions continuously innovates to enable faster and more personalized diagnosis and therapies in molecular imaging. Hermes Medical Solutions was first to develop SPECT reconstruction software and dual-head whole-body scanning and first to introduce medical image fusion software for combined viewing of images from different scanners. With Hermia, we empower healthcare professionals with state-of-the-art software for all clinical scenarios into ONE vendor-neutral software suite. Combining leadership in innovation for NM/MI software with customer-driven service is our mission and our success lies in our close and longstanding collaboration with our customers to meet their software, support, and service needs. The result is improved quality in patient management and decision support for thousands of healthcare providers and their patients worldwide.
www.hermesmedical.com

Contact

Bridget Watson
Chief Marketing Officer

Hermes Medical Solutions AB (HQ)
Strandbergsgatan 16
112 51 Stockholm, Sweden
Tel: +46 76 076 47 28
bridget.watson@hermesmedical.com